These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 9661039

  • 1. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to BAY 12-8039, trovafloxacin, and ciprofloxacin.
    Hoppe JE, Dalhoff A, Pfründer D.
    Antimicrob Agents Chemother; 1998 Jul; 42(7):1868. PubMed ID: 9661039
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. In vitro activity of gemifloxacin and other antimicrobial agents against isolates of Bordetella pertussis and Bordetella parapertussis.
    Mortensen JE, Rodgers GL.
    J Antimicrob Chemother; 2000 Apr; 45 Suppl 1():47-9. PubMed ID: 10824032
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to four fluoroquinolones (levofloxacin, d-ofloxacin, ofloxacin, and ciprofloxacin), cefpirome, and meropenem.
    Hoppe JE, Rahimi-Galougahi E, Seibert G.
    Antimicrob Agents Chemother; 1996 Mar; 40(3):807-8. PubMed ID: 8851619
    [Abstract] [Full Text] [Related]

  • 6. In vitro activities of six fluoroquinolones against Canadian isolates of vancomycin-sensitive and vancomycin-resistant Enterococcus species.
    Zhanel GG, Karlowsky JA, Hoban DJ.
    Diagn Microbiol Infect Dis; 1998 Jun; 31(2):343-7. PubMed ID: 9635908
    [Abstract] [Full Text] [Related]

  • 7. Single- and multistep selection study of the antipneumococcal activity of BMS-284756 compared to ciprofloxacin, levofloxacin, trovafloxacin and moxifloxacin.
    Clark CL, Nagai K, Davies TA, Bozdogan B, Dewasse B, Jacobs MR, Appelbaum PC.
    Clin Microbiol Infect; 2002 Jun; 8(6):373-80. PubMed ID: 12084107
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. In vitro development of resistance to three quinolones in Streptococcus pneumoniae.
    Rodríguez JC, Llinares F, Royo G.
    Chemotherapy; 2001 Jun; 47(1):39-42. PubMed ID: 11125231
    [Abstract] [Full Text] [Related]

  • 12. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
    Klepser ME, Ernst EJ, Petzold CR, Rhomberg P, Doern GV.
    Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. [Bactericidal activity of Trovafloxacin and Moxifloxacin against Gram-negative anaerobic bacilli].
    Bosnea D, Stadoleanu C, Boswell FJ, Buiuc D.
    Rev Med Chir Soc Med Nat Iasi; 2000 Mar; 104(4):117-22. PubMed ID: 12089939
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Comparative in vitro activities of ciprofloxacin, clinafloxacin, gatifloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Klebsiella pneumoniae, Klebsiella oxytoca, Enterobacter cloacae, and Enterobacter aerogenes clinical isolates with alterations in GyrA and ParC proteins.
    Brisse S, Milatovic D, Fluit AC, Verhoef J, Martin N, Scheuring S, Köhrer K, Schmitz FJ.
    Antimicrob Agents Chemother; 1999 Aug; 43(8):2051-5. PubMed ID: 10428935
    [Abstract] [Full Text] [Related]

  • 20. In vitro activity of gatifloxacin compared with gemifloxacin, moxifloxacin, trovafloxacin, ciprofloxacin and ofloxacin against uropathogens cultured from patients with complicated urinary tract infections.
    Naber KG, Hollauer K, Kirchbauer D, Witte W.
    Int J Antimicrob Agents; 2000 Nov; 16(3):239-43. PubMed ID: 11091042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.